Acquisition Opportunity Jubilee Clinical Research was acquired by Pinnacle Clinical Research (via LongueVue Capital) in September 2024, signaling potential integration of site networks, shared vendors, and expanded trial capabilities. This creates cross-sell opportunities for additional therapeutic areas and larger multi-site collaboration.

Diverse Therapeutics As a multi-therapeutic site with ongoing studies in diabetes, cardiovascular, dermatology, infectious disease and more, JCR offers access to a broad patient population and can be a target for partnerships on both early and late phase trials across multiple indications.

Boutique Scale Operating with a lean team (2-10 employees) but backed by a history of experienced investigators, JCR may be receptive to scalable CRO support, add-on services, or co-management agreements to handle increased study demand without large fixed overhead.

Local and Philanthropic Focus Founded with a mission to eliminate poverty and suffering and partnered with Operation H.O.P.E., JCR emphasizes community impact and patient-centric approaches. This alignment can be leveraged for patient recruitment initiatives, community engagement programs, and socially responsible collaborations that enhance trial enrollment.

Digital and Compliance Readiness Technical stack includes Wix, Webpack, reCAPTCHA, Google Analytics, and other modern web tools, suggesting a baseline readiness for digital trial recruitment, patient portals, and secure online data collection. This can inform proposals for enhanced digital engagement, eConsent, and regulatory-compliant patient outreach.